...BRCA1-associated breast malignancies to cisplatin. This breakthrough has revived interest to the treatment of cancer in ...
...BRCA1/2. However, questions regarding their wider use persist and other determinants of responsiveness to PARP inhibitor...
...BRCA1 profile (P = .04). Analysis of the combined expression of PARP1 and BRCA1 revealed that high expression of PARP1 i...
...BRCA1-associated FANCJ helicase is among those helicases able to unwind G4 DNA in vitro, and FANCJ mutations are associa...
...BRCA1 and BRCA2, the research community moved to candidate gene studies that led to the identification of ATM, BRIP1, CH...
...BRCA1/2. Understanding of the mortality in hereditary cancer predisposing diseases is important for developing effective...
...BRCA1/2 mutations (P = .03).,Parity may have different roles in the development of PABC versus other premenopausal breas...
...BRCA1 and/or BRCA2 mutation carriers.,Analysis of pooled observational cohort data, self-reported at enrollment and at f...
Breast cancer gene 1 (BRCA1) deficient cells not only are hypersensitive to double-strand breaks but also are hypersensi...
...BRCA1 C-terminal (BRCT) domains recognizes poly(ADP-ribose) (PAR) both in vitro and in vivo. Among these FHA and BRCT do...
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
